About The Study: Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart, a novel monoclonal antibody, reduced polyp size and severity of nasal symptoms at 24 weeks.
Corresponding Authors: To contact the corresponding authors, email Luo Zhang, MD, ( dr.luozhang@139.com ) and Chengshuo Wang, MD, ( wangcs830@126.com ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.12515)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.12515?guestAccessKey=3d50dfd6-5eae-4dc7-9a7c-dc565d9f5f21&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081825
JAMA